---
title: "19:00 ET
			
			
				Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/272192951.md"
description: "Argo Biopharmaceutical Co., Ltd. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 1:15 PM PST. Dr. Dongxu Shu, the CEO, will lead the presentation. Argo Biopharma focuses on developing next-generation siRNA therapies, with a pipeline of six RNAi candidates targeting various diseases, including cardiovascular and viral infections."
datetime: "2026-01-12T00:00:26.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/272192951.md)
  - [en](https://longbridge.com/en/news/272192951.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/272192951.md)
---

# 19:00 ET
			
			
				Argo Biopharma to Present at the 44th Annual J.P. Morgan Healthcare Conference

, /PRNewswire/ -- Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage biotechnology company committed to developing next-generation siRNA therapies, today announced that Dr. Dongxu Shu, Co-Founder, Chairman of the Board, and Chief Executive Officer will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15th 2026 at 1:15 PM PST / 4:15 PM EST. in San Francisco, CA.

**About Argo Biopharma**

Argo Biopharma is a clinical-stage biotechnology company committed to developing next-generation RNAi therapeutics to provide better treatment options for patients worldwide. The company has established a robust and diverse pipeline of RNAi molecule candidates targeting a wide range of indications, including cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases. Currently, Argo Biopharma has six RNAi candidates in clinical development.

For more information, visit www.argobiopharma.com.

SOURCE Argo Biopharmaceutical Co., Ltd

## Related News & Research

- [Process intensification: Separating fact from fiction](https://longbridge.com/en/news/287797837.md)
- [Phase 2b/3 cardiovascular diseases biotech Kardigan files for a $100 million IPO](https://longbridge.com/en/news/287684932.md)
- [15:00 ETSolu Therapeutics Granted FDA Fast Track Designation for STX-0712 for Treatment of Chronic Myelomonocytic Leukemia](https://longbridge.com/en/news/287810311.md)
- [Number of shares and votes in BioArctic AB (publ) as of May 29, 2026](https://longbridge.com/en/news/288139530.md)
- [11:11 ETCellCarta and Sonic Healthcare Establish Strategic Partnership to Commercialize Companion Diagnostics Through Lab Network](https://longbridge.com/en/news/287792346.md)